Entyvio 300 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FQSU7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $24,403
Award facts
- Contract value 100% obligated
- $24,403.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $24,403.40 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Entyvio 300 mg vials. The award, issued December 2, 2025, with an ultimate completion date of December 3, 2025, utilizes a firm fixed-price delivery order structure with no set-aside designation. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (SPE2DR) through the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical supply support to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial federal contracting capability as an established prime vendor under the PPV-G GEN V program, which carries a ceiling value of $499,999,999 and extends through December 31, 2036. The company's extensive product portfolio encompasses branded and generic pharmaceuticals, biologics, vaccines, and medical consumables, with recent delivery orders reflecting DLA's reliance on the contractor for specialized therapeutic products. As the sole prime contractor on this delivery order with no subcontractor involvement identified, DMS Pharmaceutical Group continues to serve as a critical pharmaceutical supplier supporting military medical operations through the Defense Logistics Agency's Medical Supply Chain division.
Quick answers
Who was awarded contract SPE2DR26FQSU7?
SPE2DR26FQSU7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 2, 2025.
How much is contract SPE2DR26FQSU7 worth?
The government has obligated $24,403 on SPE2DR26FQSU7.
Is contract SPE2DR26FQSU7 an order under another contract?
Yes. SPE2DR26FQSU7 is a delivery order under SPE2DR25D9214, an indefinite delivery contract.
Was contract SPE2DR26FQSU7 competed?
The extent of competition for SPE2DR26FQSU7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award